MI-LINEAGE-LOGISTICS
2.11.2021 08:02:13 CET | Business Wire | Pressemeddelelse
Lineage Logistics, LLC (”Lineage” eller ”selskabet”), en førende global udbyder af temperaturstyret industriel REIT og logistikløsninger, meddelte i dag, at de har afsluttet opkøbet af køleopbevaringsafdelingen i Claus Sørensen Gruppen, en anerkendt operatør inden for køleopbevaring i Danmark.
Købet blev først annonceret den 15. juni 2021.
Udvidelsen i Danmark er en afgørende del af Lineages vækstplaner i Norden. Opkøbet giver Lineages globale rækkevidde en vigtig forbindelse til Danmark, som er ved at udvikle sig til et førende europæisk midtpunkt inden for den globale køleopbevaringsforsyningskæde, med luftfragt og søfartsinfrastruktur i verdensklasse.
Virksomhedens nuværende tilstedeværelse i Danmark forstærkes igennem Lineages opkøb af Claus Sørensen og tilføjer betydelige volumener på strategiske lokationer nær danske havne og centre for fødevareproduktion.
”Claus Sørensens relationer og tilgang til forretning vil sætte skub i vores vækstplaner i Norden”, siger Harld Peters, Senior Vice President for Europa hos Lineage. ”Vi ser frem til at arbejde sammen med dem for at betjene vores kunder i hele Europa”.
Claus Sørensen, som har hovedkvarter i Esbjerg, har en kapacitet på næsten en million kubikmeter og 200.000 pallepositioner fordelt på ni lagre og mere end 250 teammedlemmer. Med opkøbet og færdiggørelsen af igangværende byggeri i regionen, vil Lineages samlede fodaftryk i Danmark omfatte 17 lokationer og næsten 300.000 pallepositioner.
Claus Sørensen leverer køleopbevaring til kød og fjerkræ, brød, is, færdigretter, frugt og grønt og mejeriprodukter. Ud over opbevaring leverer virksomheden blæsefrysning, kvalitetskontrol, ordresammensætning og pakning, isproduktion, told og distribution til detailhandel og catering. Claus Sørensen kan fryse 1.800 tons produkter om dagen. Claus Sørensen er som et vigtigt led i den danske fødevare- og drikkevareforsyningskæde gået sammen med sine kunder for at forbedre deres forsyningskædeoperationer, opnå maksimal energiudnyttelse og beskytte miljøet.
”Lineage er stærkt engagerede i både innovation og service, hvilket passer perfekt til vores mangeårige forpligtelse til at være vores kunders foretrukne partner”, siger Jesper Toft Mathiasen, CEO hos Claus Sørensen. ”Vi glæder os til at blive en del af en virksomhed, der deler vores værdier, og til at slå os sammen med Lineages team i regionen for at transformere vores kunders forsyningskæde og hjælpe dem med at få deres forretninger til at vokse”.
Lineage Logistics kom ind på det nordiske marked i 2020. Siden da har virksomheden opkøbt Lundsøe Køl & Frys A/S med kølelagerfaciliteter i Nordjylland og Aarhus, Super Frost Sjælland ApS og Coldstar ApS, udover opkøbet af Claus Sørensen.
Om Lineage Logistics: Lineage Logistics er en førende udbyder af temperaturstyret industriel REIT og logistikløsninger. Firmaet har et globalt netværk på over 400 strategisk placerede faciliteter med en samlet kapacitet på over 60 millioner kubikmeter, der spænder over 19 lande fra Nordamerika, Europa og Asien-Stillehavsområdet. Lineages ekspertise indenfor brugsklare løsninger, deres uovertrufne netværk af fast ejendom og udvikling af innovativ teknologi er med til at øge distributionseffektiviteten, fremme bæredygtighed, minimere spild i forsyningskæden og, vigtigst af alt, som visionær partner med Feeding America, være med til at brødføde verden. Som en anerkendelse af firmaets initiativer inden for innovation og bæredygtighed opnåede Lineage at blive nr. 17 på CNBC Disruptor 50-listen i 2021, nr. 1 som bedste datavidenskabsvirksomhed og samlet nr. 23 på Fast Companys liste over verdens mest innovative virksomheder i 2019, udover at være med på Fortunes Change The World-liste i 2020. (www.lineagelogistics.com )
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20211102005519/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
